FDA clears expanded use of Pfizer's breast cancer med IBRANCE

FDA clears expanded use of Pfizer's breast cancer med IBRANCE


The FDA approves Pfizer's supplement New Drug Application for IBRANCE . It is now cleared for the treatment of hormone receptor-positive , human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in combination with fulvestrant [AstraZeneca's FASLODEX ] in women with disease progression following endocrine therapy.



from Biotech News